|By PR Newswire||
|February 4, 2014 02:00 AM EST||
LONDON, February 4, 2014 /PRNewswire/ --
Shield Therapeutics (Shield), an independent specialty pharmaceutical company, today announces the acceptance of the first peer-reviewed abstract relating to data from the AEGIS Phase III programme of ST10 for the treatment of iron deficiency anaemia (IDA) in inflammatory bowel disease (IBD). The data will be presented at the 9th Congress of ECCO, taking place from February 20 - 22 in Copenhagen, Denmark.
As recently announced, ST10, a novel orally-dosed form of ferric iron, successfully met both the primary and secondary endpoints of the AEGIS pivotal Phase III programme. With a mean increase of 2.3g/dL in ST10-treated subjects, the results of the study strongly demonstrated ST10's potential to be the only effective oral treatment for ferrous intolerant IDA patients, in addition to being an effective alternative to intravenous iron treatment.
The abstract about ST10, entitled "Correcting iron deficiency anaemia in IBD: A pivotal phase 3 study of a novel oral ferric iron", will be presented during the Digital Oral Poster Session 9 - Therapy today - in Room 9, Hall B on the Ground level of the Bella Centre at 13.07 on Friday 21st February 2014.
About Shield Therapeutics
Shield Therapeutics (http://www.shieldtherapeutics.com), founded in 2008, is an independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need. Shield has successfully completed a pivotal Phase 3 programme of its lead asset, ST10, for the treatment of iron deficiency anaemia associated with inflammatory bowel disease and is soon to commence a Phase 3 study of ST10 for the treatment of iron deficiency anaemia in patients with chronic kidney disease.
For more information about Shield Therapeutics, please contact:
Consilium Strategic Communications
Mary-Jane Elliott / Emma Thompson / Lindsey Neville
Email: [email protected]
Aug. 25, 2016 10:45 PM EDT Reads: 1,854
Aug. 25, 2016 10:15 PM EDT Reads: 1,706
Aug. 25, 2016 09:15 PM EDT Reads: 2,187
Aug. 25, 2016 09:00 PM EDT Reads: 1,691
Aug. 25, 2016 08:45 PM EDT Reads: 1,371
Aug. 25, 2016 06:30 PM EDT Reads: 1,918
Aug. 25, 2016 05:15 PM EDT Reads: 643
Aug. 25, 2016 04:15 PM EDT Reads: 433
Aug. 25, 2016 03:30 PM EDT Reads: 1,490
Aug. 25, 2016 03:15 PM EDT Reads: 2,216
Aug. 25, 2016 02:00 PM EDT Reads: 3,547
Aug. 25, 2016 01:00 PM EDT Reads: 3,892
Aug. 25, 2016 01:00 PM EDT Reads: 2,596
Aug. 25, 2016 12:45 PM EDT Reads: 592
DevOps at Cloud Expo – being held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA – announces that its Call for Papers is open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's largest enterprises – and delivering real results. Am...
Aug. 25, 2016 12:15 PM EDT Reads: 3,387